Skip to main content
. 2018 May 29;3:63. [Version 1] doi: 10.12688/wellcomeopenres.14576.1

Table 6. DOLORisk cohorts approvals.

NT: Neuroscience Technologies. INSERM : Institut National de la Santé Et de la Recherche Médicale. CS: cross-sectional. Pro: prospective. REC: Research Ethics Committee. ANSM: Agence nationale de sécurité du médicament et des produits de santé (national agency for medicines and health products safety). CPP : Comité de protection des personnes (ethical research committee). CCTIRS: Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de la santé (advisory committee on data processing in health research). CNIL: Commission nationale de l’informatique et des libertés (data protection authority).

Centre CS or
Pro		 Aetiology Anticipated
sample size		 Ethics
committee		 Ethics
reference		 Registration link Reference End date
Dundee Pro Mixed 5500 Tayside
Committee
on Medical
Research Ethics		 05/S1401/89 https://www.hra.nhs.uk/planning-
and-improving-research/
application-summaries/research-
summaries/dolorisk-dundee/ 		Smith, et al. 47 April 2018
Yorkshire & The
Humber - South
Yorkshire REC		 15/YH/0285
Dundee Pro Diabetes 3000 Tayside
Committee
on Medical
Research Ethics		 053/04 https://clinicaltrials.gov/ct2/show/
NCT02783469 		Hebert, et al. 48
Yorkshire & The
Humber - South
Yorkshire REC		 15/YH/0285
Oxford CS Extreme
phenotypes		 100 NRES
Committee
London -
Riverside		 12/LO/0017 https://clinicaltrials.gov/ct2/show/
NCT02696746 		January
2019
CS Diabetes 300 West London
REC 3		 10/H0707/35 https://clinicaltrials.gov/ct2/show/
NCT02672059 		Themistocleous,
et al. 5 		June 2019
Imperial CS Diabetes 200 London -
Bromley REC		 16/LO/1470
Kiel CS Mixed 200 Ethics
Committee of
the Faculty of
Medicine of Kiel
University		 D454/16 https://clinicaltrials.gov/ct2/show
NCT02666456 		March
2019
Technion CS Diabetes 200 Helsinki
Committee of
Rambam Health
Care Campus		 0052-15-RNB https://clinicaltrials.gov/ct2/show/
NCT02402361 		July 2018
NT CS Diabetes 100 Clinical
Research Ethics
Committee
(CREC) of
idcsalud
in Catalonia		 2016/43-NEU-
MC Mutual		 https://clinicaltrials.gov/ct2/show/
NCT02985294 		March
2019
CS Traumatic 100
Aarhus CS Diabetes 350 Central
Denmark Region
Committees on
Health Research
Ethics		 Diabetic
neuropathy, 1-
10-72-130-16		 https://clinicaltrials.gov/ct2/show/
NCT02947828 		May 2018
CS Chemotherapy 70 Central
Denmark Region
Committees on
Health Research
Ethics		 Chronic
neuropathy
following
chemotherapy,
20110158		 https://clinicaltrials.gov/ct2/show/
NCT02654691 		April 2017
Pro Chemotherapy 50 Central
Denmark Region
Committees on
Health Research
Ethics		 Acute and
chronic
neuropathy after
oxaliplatin, 1-10-
72-154-16
Aarhus Pro Post-surgical 250 Central
Denmark Region
Committees on
Health Research
Ethics		 Understanding
risk factors and
determinants for
neuropathic pain
after lung or
breast surgery,
1-10-72-254-16
and 1-10-72-
23-17		 https://clinicaltrials.gov/ct2/show/
NCT03124511
https://clinicaltrials.gov/ct2/show/
NCT02960971 		November
2019
INSERM Pro Post-surgical 340 ANSM 160106B-32,
160287B-32		 https://clinicaltrials.gov/ct2/show/
NCT02944721 		November
2020
CPP CPP/2-16, 16
03 18
CCTIRS 16-331bis, 16-
330bis
CNIL 2007306 v 0,
1251929 v 0